Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated With the Peginterferon-Ribavirin Combination

Bani‐Sadr, Firouzé; Denoeud, Lise; Morand, Patrice; Lunel‐Fabiani, Françoise; Pol, Stanislas; Cacoub, Patrice; Perronne, Christian; Carrat, Fabrice

doi:10.1097/qai.0b013e318040b2b6

Cited by 79 publications

(54 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With current assays, false negative antibody tests are rare in chronic infection but may be a problem in early acute infection [183][184][185][186][187]. Consideration should be given to HCV RNA testing of HCV antibody-negative HIVpositive individuals where: acute infection is suspected; there are unexplained abnormal liver function tests (rare).…”

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

“…Diagnosis of chronic infection is usually made on the basis of a positive anti-HCV anti body test [enzyme-linked immunosorbent assay (ELISA) AE recombinant immunoblot assay (RIBA)], confirmed by a positive HCV RNA [reverse transcriptase-polymerase chain reaction (RT-PCR)] test. However, a proportion of patients will have normal liver enzymes or a negative antibody test in the presence of chronic HCV viraemia [183][184][185][186][187].…”

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

“…Over time, anti-HCV antibody levels decline such that it can be difficult to differentiate infection in the distant past from nonspecific false positivity [183][184][185][186][187].…”

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

“…RNA levels may be transiently undetectable during acute infection so it is particularly important to repeat HCV RNA tests in patients if the time at which they were initially infected is unknown [183][184][185][186][187].…”

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

See 3 more Smart Citations

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

et al. 2009

View full text Add to dashboard Cite

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

“…Over time, anti-HCV antibody levels decline such that it can be difficult to differentiate infection in the distant past from nonspecific false positivity [183][184][185][186][187].…”

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

Section: Diagnosis Of Hcv Infection In Hiv-infected Individualsmentioning

confidence: 99%

See 2 more Smart Citations

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

et al. 2009

View full text Add to dashboard Cite

“…. Abacavir: several studies have reported poorer outcome of HCV treatment following concurrent therapy with abacavir [65]. Both abacavir and ribavirin are guanosine analogues and thus intracellular interference may result in lower levels of the active phosphorylated moiety.…”

Section: Preparations Prior To Therapymentioning

confidence: 99%

Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations

Lagging

Wejstål

Uhnoo

et al. 2009

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV

Nicot¹,

Abravanel²,

Lafont³

et al. 2008

Journal of Medical Virology

View full text Add to dashboard Cite

The hepatitis C virus (HCV) infects a substantial proportion of patients infected with human immunodeficiency virus (HIV). Patients infected with both HCV and HIV respond poorly to anti-HCV treatment with pegylated interferon alpha and ribavirin. But few data are available on the influence of ribavirin and interferon concentrations on treatment outcome for these patients. This study investigated the relationship between the serum pegylated interferon and ribavirin concentrations 3 and 6 months after treatment initiation, and treatment outcome in 35 HCV-HIV coinfected patients. The pegylated interferon and ribavirin concentrations at months 3 and 6 were similar. The pegylated interferon concentrations at 3 months in responders and nonresponders were similar. However, responders tended to have higher ribavirin concentrations (2,322 ng/ml) than nonresponders (1,833 ng/ml; P = 0.08). Responders infected with HCV genotype 1 or 4 had higher ribavirin concentrations (2,672 ng/ml) than did similarly infected nonresponders (1,758 ng/ml; P = 0.04). ROC curve analysis showed that a ribavirin concentration of 2,300 ng/ml was the best threshold for predicting a nonresponse (ROC area = 0.80 +/- 0.12). Thus ribavirin concentrations influence treatment outcome in HIV patients infected with HCV genotype 1 or 4. Monitoring ribavirin concentrations could help adapt ribavirin concentrations and improve the sustained virological response.

show abstract

Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated With the Peginterferon-Ribavirin Combination

Cited by 79 publications

References 7 publications

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations

Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV

Contact Info

Product

Resources

About